共查询到18条相似文献,搜索用时 500 毫秒
1.
中国抗癌协会神经内分泌肿瘤专业委员会 《中国肿瘤临床》2023,50(8):385-397
神经内分泌肿瘤(neuroendocrine neoplasms,NENs)是一类起源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物的少见肿瘤,可发生于全身各处,以肺及胃肠胰NEN(gastroentero-pancreatic neuroendocrine neoplasms,GEP-NENs)最常见。国内外研究数据提示,NENs的发病率在不断上升。美国流行病学调查结果显示,与其他类型肿瘤相比,NENs的发病率上升趋势更为显著。中国抗癌协会神经内分泌肿瘤专业委员会在现有循证医学证据基础上,结合已有国内外指南和共识,制订了首版中国抗癌协会神经内分泌肿瘤整合诊治指南,为临床工作者提供参考。 相似文献
2.
3.
摘 要:神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一类起源于神经内分泌细胞和肽能神经元的罕见肿瘤。功能性神经内分泌肿瘤(functional neuroendocrine neoplasm,F-NEN)可以通过合成并分泌大量的肽、胺等相关激素,引起特异性临床表现,严重影响患者健康。F-NEN具有高度异质性,诊断困难且复杂,临床管理既需改善临床表现和控制肿瘤进展,又要实施个性化治疗。近年来,基于特异性靶点如生长抑素受体在临床诊疗研究中取得了突破性进展,为晚期NEN患者带来了生存希望。全文对F-NEN进行梳理,综述其诊断及治疗进展。 相似文献
4.
5.
摘 要:神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一种罕见的肿瘤,源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物。近年来,核医学诊疗一体化分子探针在NEN的诊断和治疗方面取得了显著的临床进展,为该病的管理提供了新的视角。放射性核素标记分子探针在NEN的诊断中展现了全身特异性显像的优势,可用于早期诊断、临床分期、复发转移监测以及随访评估,有助于为患者制定更精准的治疗方案。同时,治疗放射性核素标记的分子探针在NEN的治疗中也展现了显著的临床疗效,为患者带来了新的治疗选择。全文综述各种新型核医学分子探针在NEN的诊断和治疗中的应用和研究进展。 相似文献
6.
《中国肿瘤临床与康复》2019,(8)
<正>神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一种罕见的异质性肿瘤[1],一般起源于神经内分泌细胞,占所有神经内分泌肿瘤的1%~2%[2],对人体健康有很大危害。这种肿瘤可出现在人体任何部位,且具有很高的转移倾向。这类肿瘤早在1907年就被命名为"类癌",其在发展过程中表现出明显的生物学特征,如惰性、低度恶性和转移性等[3]。相关研究结果表明,胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,pNENs)约占神经内分泌肿瘤的 相似文献
7.
8.
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是起源于肽能神经元和神经内分泌细胞的异质性肿瘤,好发于胃、肠、胰腺、肝脏、胆管、肺及甲状腺等器官,其中以胃肠胰神经分泌肿瘤最常见。根据2010年版WHO消化系统肿瘤分类标准,NEN可分为神经内分泌瘤、神经内分泌癌、混合性腺神经内分泌癌(mixed adenoneuroendocrine carcinoma,MANEC)及部份特异性和功能性NEN。我国的病理专家于2011年制定出《中国胃肠胰神经内分泌肿瘤病理学诊断共识》并于2013年再次修订。MANEC定义为同时具有腺管形成的经典型腺癌和神经内分泌肿瘤形态特点的上皮性肿瘤,且两种成分各占30%以上。结直肠MANEC的发病率低,仅占所有结直肠肿瘤的3%~9.6%,其治疗及预后等暂无定论。我们应用手术、射频消融和化疗等综合手段治疗升结肠MANEC肝转移患者1例,存活已5年,现将诊治过程报告如下。 相似文献
9.
近年来,神经内分泌肿瘤(neuroendocrine neoplasm,NEN)的治疗受到越来越多的关注,但多数治疗方案未能使肿瘤产生客观缓解。生长抑素类似物、依维莫司和舒尼替尼能显著延长患者无进展生存期(progression-free survival,PFS),但客观缓解率(objective response rate,ORR)较低。以链脲霉素为基础的化疗方案因毒性较大且在国内尚未上市,在临床使用中受到限制。一些小样本研究提示替莫唑胺联合卡培他滨(CAPTEM)有较高的ORR和较长的PFS。然而,目前鲜见CAPTEM方案的系统性综述。本文通过近年来国内外文献报道,对CAPTEM方案治疗神经内分泌肿瘤的理论基础、疗效、疗效预测生物标志物、具体给药方案及不良反应等方面作一综述。 相似文献
10.
11.
12.
13.
背景与目的:神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一组罕见的、起源于神经内分泌细胞和肽能神经元的异质性肿瘤,近年来发病率呈不断上升的趋势。本研究旨在分析大连地区NEN的流行病学和临床病理学特征,为防治NEN提供依据。方法:采用回顾性调查方法,收集2000-2013年经大连医科大学附属第一医院病理科证实的NEN患者,研究其流行病学特征、病变部位和病理类型,并对性别、年龄等因素进行统计学分析。结果:共有NEN患者279例,总检出率2.58/万人,男性166例,女性113例,男女比例为1.47∶1,患者的平均年龄(59.4±17.1)岁(20~83岁),男性平均年龄(58.9±19.4)岁(20~81岁),女性平均年龄(61.7±15.0)岁(29~83岁),不同性别的检出率及年龄差异无统计学意义。病变部位以消化系统最为常见(71.68%),肺和支气管次之(20.79%),纵隔、乳腺、子宫等其他部位较罕见,不同性别在病变部位上差异无统计学意义(P>0.05)。NEN的3种病理类型中,神经内分泌瘤(neuroendocrine tumor,NET)132例(47.31%),神经内分泌癌(neuroendocrine cancer,NEC)140例(50.18%),混合性腺神经内分泌癌(mixed adenoneuroendocrine carcinoma,MANEC)7例(2.51%),不同性别的病理类型差异无统计学意义(P>0.05),不同年龄段间的NET和NEC差异有统计学意义(P<0.05),MANEC无统计学意义(P>0.05)。结论:大连地区的NEN检出率近年呈上升趋势,应注意该病的早期筛查和防治。 相似文献
14.
Boris G. Naraev Robert A. Ramirez A. Tuba Kendi Thorvardur R. Halfdanarson 《Clinical lung cancer》2019,20(3):e376-e392
Neuroendocrine neoplasms (NEN) are a family of malignancies of diverse origin, including the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated neuroendocrine tumors (NET) classified as typical carcinoids or atypical carcinoids, and poorly differentiated neuroendocrine carcinomas classified as small-cell lung carcinoma or large-cell neuroendocrine carcinoma. According to a recent analysis of a large, population-based registry, approximately one-third of all patients with lung typical/atypical carcinoids have distant metastases at diagnosis, and median survival for these patients is 24 months. At present, only 1 therapy is approved by the US Food and Drug Administration (FDA) for patients with advanced lung typical/atypical carcinoids, everolimus, indicating a clear need for more treatment options in this patient population. Although not yet supported by results from randomized prospective trials, somatostatin analogues are considered an acceptable treatment option for patients with lung typical/atypical carcinoids expressing somatostatin receptors. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE was recently approved by the FDA for the treatment of gastroenteropancreatic NET; however, the role of PRRT in patients with lung typical/atypical carcinoids remains unclear, because they were not included in the pivotal NETTER-1 (Neuroendocrine Tumors Therapy) trial. Herein we provide a comprehensive review of the available clinical evidence for efficacy and safety of PRRT in patients with lung typical/atypical carcinoids. On the basis of the preliminary evidence of efficacy and the consistent safety profile in this patient group, we propose that experienced multidisciplinary NET teams may consider PRRT alongside everolimus as an option for patients with advanced somatostatin receptor-positive lung typical/atypical carcinoids whose disease is progressing during first-line treatment with somatostatin analogues. 相似文献
15.
Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors, whose incidence and prevalence are increasing. The clinical behavior of NEN is variable, ranging from well-differentiated slow growing tumors to highly aggressive poorly differentiated neuroendocrine carcinomas. The term carcinoid is commonly used for the more benign variants of these neoplasms. Most frequently, carcinoids have their origin in the small intestine, followed by in the lung and other sites. Some of these tumors are associated with the carcinoid syndrome. The use of somatostatin analogs has revolutionized the clinical management of patients with carcinoids. However, although symptomatic relief and stabilization of tumor growth for various periods of time are observed in many patients treated with somatostatin analogs, tumor regression is rare. Currently, there is no other powerful antiproliferative agent available for carcinoids. Mammalian target of rapamycin (mTOR), a main protein kinase in the phosphoinositide 3-kinase/Akt/p70S6K signaling pathway, is an important intracellular mediator involved in multiple cellular functions including proliferation, differentiation, apoptosis, tumorigenesis, and angiogenesis. Alterations of the normal activity of mTOR and of mTOR-related kinases in this pathway have been found in a diversity of human tumors, including NEN; therefore, mTOR pathway represents an attractive target for new anticancer therapies. While mTOR inhibitors, such as everolimus, are established therapy in pancreatic NEN, results from recent clinical trials indicate that mTOR inhibitors may be also of value in the management of carcinoids. However, further clinical trials will have to confirm efficacy and elucidate, in which subtypes and in which setting, these drugs might be most usefully applied. 相似文献
16.
17.
Masui Toshihiko Ito Tetsuhide Komoto Izumi Kojima Shinsuke Kasai Yosuke Tanabe Minoru Hara Kazuo Hirano Satoshi Okusaka Takuji Ichikawa Yasushi Kinugasa Yusuke Kokudo Norihiro Kudo Atsushi Sakurai Akihiro Sugihara Kenichi Date Hiroshi Haruma Ken Hijioka Susumu Hirata Koichi Yamano Hiroo Sakamine Motohiro Kikuchi Takashi Fukushima Masanori Imamura Masayuki Uemoto Shinji 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(5):840-849
International Journal of Clinical Oncology - Neuroendocrine neoplasm (NEN) is a comparatively rare tumor that has been considered indolent. Due to these characteristics, detailed epidemiological... 相似文献
18.
目的:分析河南地区神经内分泌肿瘤(neuroendocrine neoplasm,NEN)的流行病学和病理学特征,为NEN的防治提供依据。方法:回顾性调查2010年1月至2015年12月经河南省人民医院病理科确诊的NEN患者,综合分析其流行病学及病理学特征。结果:共检出NEN患者218例,总检出率为0.09%;年检出率的差异具有统计学意义(P<0.05);男性117例,女性101例,比例为1.16∶1;平均年龄(51.19±13.97)岁,男性平均年龄(52.86±13.10)岁,女性平均年龄(49.24±14.76)岁。三种病理类型中神经内分泌瘤(NET)104例(47.71%),神经内分泌癌(NEC)107例(49.08%),混合性腺神经内分泌癌(MANEC)7例(3.21%),不同性别NEN的病理类型差异无统计学意义(P>0.05)。NEN高发年龄为40~69岁,不同年龄段的NET和NEC差异有统计学意义(P<0.05)。病变部位以胰腺(22.02%)最为常见,其次为肺(15.14%),小脑、鼻、喉部、宫颈、卵巢等其他部位较罕见,除甲状腺外,不同性别在病变部位上的差异无统计学意义(P>0.05)。肿瘤组织标本的取得方式中以传统的手术为主(51.38%),其次是内镜方式(44.49%)。嗜铬蛋白A(CgA)染色阳性156例(71.56%);突触素(SYN)染色阳性203例(93.12%);NET、NEC中SYN阳性率均高于CgA阳性率,差异具有统计学意义(P<0.05)。结论:河南地区NEN的检出率近年呈上升趋势,熟悉其流行病学和病理学特征对早期诊断、防治及降低该地区NEC的发生具有重要的意义。 相似文献